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Abstract 
Aim 
To survey United Kingdom (UK) cellular pathology departments regarding their attitudes 
and practices relating to release of human tissue from their diagnostic archives for use in 
clinical trial research. 
Methods 
A 30-item questionnaire was circulated to the National Cancer Research Institute’s (NCRI) 
Cellular Molecular Pathology Initiative (CM-Path) and Confederation of Cancer Biobanks 
(CCB) mailing lists. Responses were collected over a ten-month period from November 2016 
to August 2017. 
Results 
38 departments responded to the survey, the majority of which regularly receive requests 
for tissue for research purposes. Most requests come from academia and financial support 
to facilitate tissue release comes from a variety of sources. A range of practices were 
reported in relation to selection of the most appropriate sample to release, consent 
checking, costings and governance frameworks. 
Conclusions 
This survey demonstrates wide variation in practice across the UK and identifies barriers to 
release of human tissue for clinical trial research. Until we can overcome these obstacles, 
patient samples will remain inaccessible to research. Therefore, this study highlights the 
urgent need for clear and co-ordinated national guidance on this issue. 
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Introduction 
Straddling the interface between basic research and medical practice, clinical trials play a 
vital role in improving healthcare [1]. Tissue-based analyses are critically important in trials 
[2-4]; for example, pathology review for trial entry or outcome determination and 
biomarker testing to inform treatment allocation. Unfortunately, there are often difficulties 
in obtaining human tissue for research [5]. In the United Kingdom (UK), human tissue 
samples are collated by both National Health Service (NHS) cellular pathology laboratories 
and academic biobanks. Access to tissue stored in biobanks is usually straight forward since 
such samples are collected for research; the situation is different, however, for the release 
of tissue from NHS diagnostic archives. Archived diagnostic material is usually held as 
formalin-fixed paraffin-embedded (FFPE) blocks, with the Royal College of Pathologists 
(RCPath) recommending retention for 30 years after initial diagnosis [6]. These guidelines 
acknowledge a tension between retention of surplus material for the patient’s future 
benefit and its immediate use for research. This is particularly relevant given the recent 
explosion of novel molecular tests that can be applied to stored tissue to direct treatment 
upon disease recurrence [7, 8]; however, it is envisaged that this need will decline as more 
testing is undertaken at the time of diagnosis [9, 10]. Ultimately, RCPath recommends that 
decisions are taken on a case-by-case basis. 
The legal and administrative frameworks underpinning tissue release from diagnostic 
archives for research are also complex. Under the Human Tissue Act (2004), the Human 
Tissue Authority (HTA) must license the storage of relevant material for research [11]. If 
tissue is released from a diagnostic archive on a regular basis, it is considered a Research 
Tissue Bank (RTB) and requires a HTA license. However, HTA licensing is not required if a 
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diagnostic archive only occasionally releases tissue upon request. The mechanisms 
responsible for managing the release of archival material for research also vary; whilst some 
centres have dedicated tissue access committees, in others laboratory staff oversee the 
process. 
Given the importance of tissue release for clinical trial research, and to understand why this 
is not always achieved, the National Cancer Research Institute’s (NCRI) Cellular Molecular 
Pathology (CM-Path) initiative surveyed the UK’s cellular pathology laboratories to ascertain 
current attitudes and practices. 
Methods 
Our survey was developed by CM-Path Clinical Trials workstream members, based on their 
own experiences and a similar study conducted in the United States of America (USA) [12]. It 
contained 30 questions with the aim of assessing: (1) current attitudes and practices; (2) 
financial implications; and (3) barriers to tissue release (Appendix 1). The survey was 
distributed through the NCRI’s CM-Path and Confederation of Cancer Biobanks (CCB) 
mailing lists using an online survey tool (www.surveymonkey.com). The questionnaire asked 
for the most appropriate individual in each department to complete it. We did not specify 
who this should be but suggestions of a tissue access committee chair or head of 
department were provided. 
The questionnaire was distributed in November 2016, with results analysed in August 2017. 
To maximise responses, periodic reminder emails were sent and departments that had not 
completed the survey were contacted. We also contacted several district general hospitals 
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not included on the initial mailing lists, since we felt that their inclusion was necessary to 
capture current practices fully. Simple summary statistics were calculated for each question, 
some of which also permitted free text responses. This manuscript has been prepared in 
accordance with the ‘Improving the quality of Web surveys: the Checklist for Reporting 
Results of Internet E-Surveys (CHERRIES)’ guidelines [13] (Appendix 2). 
Results 
Respondents (Q. 1-3) 
44 individuals completed the survey, representing 38 different departments/institutions. 6 
duplicate responses were excluded from quantitative analyses (n=38) but were included in 
qualitative analyses (n=44). Responses were received from throughout the UK (including 
England, Wales, Scotland and Northern Ireland) and were mostly from university-affiliated 
hospitals (n=26; 68.4%) with a smaller number from district general hospitals (n=9; 23.7%) 
and academic biobanks (n=3; 7.9%). Respondents included 10 departmental managers 
(26.3%), 7 tissue access committee chairs (18.4%), 4 clinical heads of department (10.5%) 
and 17 other individuals (44.7%) including biobank managers, research leads and consultant 
histopathologists. 
Tissue archives (Q. 4-7) 
The majority of departments (32; 84.2%) have split on- and off-site archives, 1 department 
(2.6%) has a fully off-site collection and 1 collection (2.6%) is split between multiple NHS 
sites. Only 3 departments (7.9%) had fully on-site collections and 1 respondent (2.6%) did 
not answer. Of the 33 departments that store human tissue off-site, 8 (24.2%) felt that this 
was a barrier to sample release, 24 (72.7%) did not and 1 (3.0%) did not know. Amongst 
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departments with off-site collections, the cost of retrieving a standard case ranged between 
£0-50 (mean £21.50). 30 departments (78.9%) reported that their tissue archives are 
covered by a HTA licence, 5 (13.2%) are not, 2 (5.3%) did not know and 1 (2.6%) did not 
reply. 
Tissue access (Q. 8-15) 
31 departments (81.6%) regularly receive requests to release human tissue for research 
(several per month), 5 (13.2%) occasionally receive requests (1 per month) and 2 (5.3%) did 
not reply. 25 departments (65.8%) have a tissue access committee whereas 11 (28.9%) do 
not; 2 respondents (5.3%) did not know whether such a committee existed. 
When asked to send tissue for a clinical trial and multiple blocks are available, the following 
practices were reported (Figure 1): 
• Submit paraffin block – 10 (26.3%);
• Submit paraffin block with conditions (e.g. block must be available for return if
required and tissue must not be exhausted) – 13 (34.2%); 
• Submit unstained sections – 5 (13.2%);
• Use histopathologist’s discretion – 6 (15.8%);
• Decline request – 0 (0.0%);
• Other – 2 (5.3%, ‘would not send multiple blocks’);
• No reply – 2 (5.3%).
When only one block is available, responses were: 
• Submit paraffin block – 4 (10.5%);
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• Submit paraffin block with conditions – 9 (23.7%);
• Submit unstained sections – 10 (26.3%);
• Use histopathologist’s discretion – 11 (28.9%);
• Decline request – 0 (0.0%);
• Other – 2 (5.3%, one respondent suggested submitting a core of tissue from the
block); 
• No reply – 2 (5.3%).
When receiving a request to send diagnostic slides for central review, departments would 
(Figure 2): 
• Submit diagnostic slides (no recuts made) – 22 (57.9%, several respondents stated
they would scan slides prior to dispatch); 
• Submit recut slides and keep original diagnostic slides – 8 (21.1%);
• Submit diagnostic slides and keep recut slides – 0 (0.0%);
• Submit scanned images of diagnostic slides – 3 (7.9%);
• Decline request – 0 (0.0%);
• Other – 4 (10.5%, ‘a combination of original slides, recuts and scanned images
depending upon the particular case’ and ‘pathologist’s discretion’); 
• No reply – 1 (2.6%).
9 departments (23.7%) stated that the availability of a mechanism to quickly and easily 
retrieve blocks upon request and/or to ensure that tissue would not be exhausted would 
change their willingness to send blocks, 21 (55.3%) stated that it would not, 6 (15.8%) were 
unsure and 2 (5.3%) did not reply. When asked whether release of tissue was dependent 
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upon the reporting pathologist’s permission, 17 departments (44.7%) answered ‘yes’, 19 
(50.0%) ‘no’ and 2 (5.3%) did not reply. 25 respondents (65.8%) felt that there is a duty on 
pathology departments to maintain diagnostic material for future testing, 8 (21.1%) felt ‘it 
depends on the specifics of the consent form’, 3 (7.9%) answered ‘don’t know’, 1 (2.6%) 
answered ‘other’ (stating that they believed that it was their duty to facilitate research) and 
1 (2.6%) did not reply (Figure 3). 
Charges for tissue release (Q. 16-23) 
23 departments (60.5%) charge for sending diagnostic blocks or slides for a trial, 11 (28.9%) 
do not and 4 (10.5%) did not reply (range £8.00-165.00, mean £63.50). 22 departments 
(57.9%) charge for cutting sections, 10 (26.3%) do not, 2 (5.3%) replied ‘other’ (‘not all the 
time, depends on the study’) and 4 (10.5%) did not reply (range £1.34-15.00 per block, 
mean £7.81). 14 departments (36.8%) charge for scanning sections, 12 (31.6%) do not, 4 
(10.5%) do not have access to a scanner, 3 (7.9%) replied ‘other’ (‘not sure’) and 5 (13.2%) 
did not reply (range £1.00-20.00 per slide, mean £10.33). When asked ‘if you charge for 
sending materials for research, have the costs been factored in to the research study?’, 6 
departments (15.8%) replied ‘always’, 15 (39.5%) ‘mostly’, 11 (28.9%) ‘sometimes’, 0 (0.0%) 
‘never’, 1 (2.6%) ‘other’ (‘possibly done by the Research and Development department’) and 
5 (13.2%) did not reply. 
2 departments (5.3%) stated that more than 50% tissue requests originate from industry, 14 
(36.8%) 5-50%, 14 (36.8%) less than 5%, 5 (13.2%) were unsure and 3 (7.9%) did not reply 
(Figure 4). 21 departments (55.3%) charge industry more than academia, 10 (26.3%) charge 
the same and 7 (18.4%) did not reply. 19 departments (50.0%) would still charge if a study 
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was on the National Institute for Health Research (NIHR) trial portfolio, 12 (31.6%) would 
not, 2 (5.3%) replied ‘other’ (‘not sure’) and 5 (13.2%) did not reply. 
A variety of funding sources to fulfil research requests were reported (Figure 5): 
• NHS – 17 (44.7%);
• NIHR Biomedical Research Centres – 4 (10.5%);
• University – 2 (5.3%);
• Mixed – 9 (23.7%);
• Other – 2 (5.3%, ‘work completed in-house and costs charged to the project’ and ‘no
specific funding’); 
• No reply – 4 (10.5%).
Consent issues (Q. 24-28) 
When asked ‘does your institution have a system of collecting consent wishes in relation to 
surplus diagnostic material when patients are undergoing surgery on the NHS consent to 
procedure form?’, 16 departments (42.1%) replied ‘yes’, 10 (26.3%) ‘no’, 10 (26.3%) ‘not 
sure’ and 2 (5.3%) did not reply. 8/16 departments (50.0%) who replied ‘yes’ felt that their 
system was ‘robust’, 5 (31.3%) ‘variable’, 2 (12.5%) ‘unreliable’ and 1 (6.3%) reported that 
their system was just being set-up and it was too early to judge. 21 departments (55.3%) 
have a specific biobank consent form that can be used for surplus diagnostic material, 9 
(23.7%) do not, 6 (15.8%) were unsure and 2 (5.3%) did not reply. When asked ‘for clinical 
trials, do you ask to see the consent form before releasing tissue?’, 21 departments (55.3%) 
replied ‘yes, always’, 8 (21.1%) ‘yes, if possible’, 3 (7.9%) ‘no’, 2 (5.3%) ‘other’ (‘consent 
checking performed by Research and Development department’), 1 (2.6%) ‘don’t know’ and 
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3 (7.9%) did not reply (Figure 6). When asked ‘for research studies that are not related to a 
clinical trial, would you require evidence of consent before releasing diagnostic archive 
material?’, 16 departments (42.1%) replied ‘yes, always’, 2 (5.3%) ‘yes, if possible’, 13 
(34.2%) ‘not necessarily if release is for a Research Ethics Committee (REC) approved 
project, the material is from the living and released anonymously (and you are sure the 
patient didn’t decline)’, 0 (0.0%) ‘no’, 3 (7.9%) ‘other’ (‘our own institution’s generic REC 
approval includes the use of the diagnostic archive’ and ‘split views … most of us believe 
that the HTA rules indicate tissue can be used if fully anonymised and that the project is REC 
approved’), 1 (2.6%) ‘don’t know’ and 3 (7.9%) did not reply. 
Other information (Q. 29 & 30) 
When asked ‘do you experience any other problems related to submission of materials for 
clinical trials or other research studies?’, a number of comments were provided: 
• Underfunding and understaffing in NHS departments;
• Lack of time;
• Poor trial organisation including lack of detail about how samples will be used and/or
specific tissue requirements; 
• Difficulty accessing relevant documents (e.g. REC applications);
• Problems with consent (tissue release not specified on consent form, inadequate
knowledge and lack of communication/education about consent in general); 
• Lack of available tissue (particularly small biopsies);
• Difficulties allocating limited material between competing studies;
• Bad experiences after sending blocks away (returned with very little tissue
remaining); 
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• Increasing numbers of patient-triggered requests to send material to other countries
for testing, with significant resource implications. 
When asked ‘are there any additional comments that you would like to make relating to this 
topic in general?’, the following issues were raised: 
• Laboratories do try to fulfil requests but research will always come second to clinical
diagnosis in the NHS; 
• Need for dedicated staff to fulfil requests (facilitating tissue requests should not be
seen as part of a pathologist’s ‘day job’); 
• Variable practices within and between centres and lack of overarching guidance;
• Suggestion that it would be helpful to have access to a centralised clinical trial and
National Research Ethics Service (NRES) document repository; 
• Loss of tissue for local research;
• Frustration when tissue requests are not treated with urgency by other hospitals.
Conclusions 
To our knowledge, this is the first attempt to gather information systematically about the 
release of tissue from diagnostic archives for clinical trial research in the UK. We received 
responses from both academic institutions and district general hospitals; with the majority 
of the UK’s teaching hospitals replying we believe that our data represent the practices of 
departments involved in large scale clinical research. Most institutions (82%) receive several 
requests per month for tissue for research. This is likely to place a significant burden on 
departments, many of which reported lack of funding and understaffing as significant 
problems. Most requests come from the academic sector but there also appears to be a 
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reasonable number from industry who are charged more by most departments. Money to 
fulfil these requests comes from a variety of sources and in several institutions comes from 
a combination of funding streams. Whilst part of this variation is likely explained by 
institutional differences in funding strategies, we are concerned that it may also reflect a 
more serious issue of general underfunding of pathology support for clinical trials. The NHS 
is the sole funding source in only 45% centres, demonstrating the need for additional 
resources to ensure continued support for trials in the face of increasing diagnostic 
workloads [14]. 
Our results also demonstrate wide variation in practices between departments. The 
majority (87%) have at least some of their archives located off-site and a sizeable minority 
of these (24%) felt that this provided an obstacle to research; furthermore, retrieval of 
samples incurs additional costs. 61% departments charge for sending slides or blocks to a 
trial with a mean of £63.50 (range = £8-165). A similar percentage (58%) charge for cutting 
sections with a mean of £7.81 per block (range = £1.34-15). Just over half of departments 
that have access to a scanner (14/26) charge for using this equipment with a mean of 
£10.33 per slide (range = £1-20). Despite this, only 6 departments (16%) stated that these 
costs were always included within trial budgets. 
Interestingly, 58% departments would release their original diagnostic sections for central 
review whilst only 8% would submit scanned images. With more departments now having 
access to a slide scanner [15], this would be an obvious solution to avoid the risk of damage 
during transit. When multiple blocks exist, 61% departments would release the block with 
or without conditions but when only one block exists, this drops to 34%. Simultaneously, the 
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number who would release the block depending upon pathologist discretion increases from 
16% to 29% and the number who would submit unstained sections increases from 13% to 
26%. These findings demonstrate that most departments take a more cautious approach 
when tissue is limited, most likely to facilitate future diagnostic testing should the need 
arise. A similar survey conducted in the USA reported that 15% departments would send the 
block when only a single block existed whereas 70% would send sections [12], thus 
demonstrating greater prudence than in the UK. No departments would refuse requests for 
tissue, reflecting widespread commitment to supporting clinical trial research. Whilst 
RCPath guidance on the inter-departmental dispatch of samples exists [16], its main focus is 
on referral for specialist opinion rather than for research. 
87% respondents felt that there is at least some duty on departments to maintain diagnostic 
material for future testing whilst none felt this is not the case. Unfortunate anecdotes 
described blocks being returned with scanty remaining tissue due to factors such as poor 
microtomy. Further comments remarked on a ‘parasitic’ relationship whereby clinical trials 
depleted tissue for local research. However, only 24% departments felt that the availability 
of a mechanism to retrieve blocks quickly upon request and/or to ensure that tissue was not 
exhausted would change their willingness to send blocks. Nevertheless, better 
communication between trial centres and pathology departments and clearer arrangements 
to prevent tissue depletion are likely to encourage a more ‘symbiotic’ relationship. 
Our survey also demonstrates disparity between departments in governance frameworks. 
Most, but not all, departments (79%) are covered by an HTA licence. Only 66% departments 
have a tissue access committee; indeed, release of tissue is dependent upon the reporting 
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pathologist’s permission in 45% departments. Only 55% respondents were certain that their 
institution has a specific biobank consent form whilst only 42% were certain that their 
hospital’s surgical consent form covers this. Furthermore, of these 42%, only half felt that 
their system is ‘robust’. When releasing tissue for clinical trials, 76% departments would ask 
to see the consent form. However, this figure falls to 47% when tissue is being release for 
studies that are not part of a clinical trial. A lack of knowledge and guidance relating to what 
constitutes acceptable tissue release practices were flagged as problems and likely explain, 
at least in part, this variation. 
In summary, it appears that the UK’s cellular pathology laboratories are committed to 
facilitating requests for tissue to support clinical trials in the face of considerable challenges. 
This commitment is critically important since trial enrolment offers patients access to 
cutting-edge treatments and thus may represent their best chance of cure. No single barrier 
to the release of tissue was apparent; instead, multiple impeding factors were identified, 
the most prominent being insufficient staffing and funding and lack of guidance as to what 
constitutes best practice. In the face of an evolving crisis in the UK’s pathology workforce, 
additional activities such as research are likely to be deprioritised [14]; we believe that 
specific funding for pathologists must be provided to ensure that their crucial support to 
trials continues. Our findings provide a springboard for tackling the identified barriers and 
for generation of national guidelines to facilitate standardisation of best practices. 
Key messages 
• Access to human tissue samples is vital to the success of clinical trials and advances in
medical science
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• This survey demonstrates a lack of consistency in human tissue release practices across
UK pathology departments
• Whilst departments appear to be committed to fulfilling tissue requests, multiple
impeding barriers were identified including lack of resources and clear guidance as to 
what constitutes best practice 
• Specific funding for pathologists must be provided to ensure that their crucial support to
trials continues 
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Figure legends 
Figure 1 – Selection of sample to send away when asked to submit tissue for clinical trial 
research. 
Figure 2 – Selection of sample to send away when asked to submit slides for clinical trial 
central review. 
Figure 3 – Responses relating to whether there is a duty on pathology departments to 
maintain tissue for future diagnostic tests. 
Figure 4 – The proportion of requests for tissue that originate from industry (as opposed to 
from academia). 
Figure 5 – Funding sources supporting staff and infrastructure to respond to requests for 
tissue release (NHS – National Health Service, BRC – National Institute for Health Research 
Biomedical Research Centre). 
Figure 6 – Consent checking prior to release of tissue for clinical trial research. 
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Figure 1 – Selection of sample to send away when asked to submit tissue for clinical trial research. 
90x95mm (300 x 300 DPI) 
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Figure 2 – Selection of sample to send away when asked to submit slides for clinical trial central review. 
90x88mm (300 x 300 DPI) 
Page 22 of 38
https://mc.manuscriptcentral.com/jclinpathol
Journal of Clinical Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 3 – Responses relating to whether there is a duty on pathology departments to maintain tissue for 
future diagnostic tests.  
90x94mm (300 x 300 DPI) 
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Figure 4 – The proportion of requests for tissue that originate from industry (as opposed to from academia). 
90x101mm (300 x 300 DPI) 
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Figure 5 – Funding sources supporting staff and infrastructure to respond to requests for tissue release (NHS 
– National Health Service, BRC – National Institute for Health Research Biomedical Research Centre).
90x106mm (300 x 300 DPI) 
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Figure 6 – Consent checking prior to release of tissue for clinical trial research. 
90x100mm (300 x 300 DPI) 
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Appendix	1	–	Questionnaire	
Background	information	–	respondents	
1. Hospital/institution	name
2. Job	title	of	person	completing	the	questionnaire
3. Details	of	your	responsibility	for	release	of	diagnostic	archive	material	for	research
Clinical	head	of	department	
Histopathology	department	manager	
Tissue	access	committee	chair	(or	equivalent)	
Other	(please	specify)	
Background	information	–	tissue	archives	
4. Where	are	your	diagnostic	archives	located?
On-site	
Off-site	(i.e.	in	a	dedicated	storage	facility)	
On-	and	off-site	(i.e.	recent	material	on-site,	older	off-site)	
Other	(please	specify)	
5. If	your	archives	are	off-site	or	partially	off-site,	is	this	a	barrier	to	research?
Yes	
No	
Don't	know	
6. If	your	archives	are	off-site	(or	partially	off-site),	what	is	the	cost	of	retrieving	one
standard	case	(standard	size	slide[s]	plus	block[s]	[i.e.	no	large	slides])?	
7. Are	your	diagnostic	archives	covered	by	a	Human	Tissue	Authority	(HTA)	licence?
Yes	
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No	
Don't	know	
Tissue	access	
8. How	often	does	your	department	receive	requests	to	submit	materials	for	research
studies?	
Regularly	(i.e.	several	requests	per	month)	
Occasionally	(i.e.	once	per	month)	
Never	
9. Do	you	have	a	tissue	access	committee	(or	equivalent)	to	evaluate	requests	to	release
tissue	(including	diagnostic	archive	material)	for	research?	
Yes	(please	provide	brief	details,	e.g.	how	often	does	it	meet,	what	is	the	
membership?)	
No	
Don't	know	
10. When	receiving	a	request	(with	appropriate	consent)	to	send	tissue	as	part	of	a	clinical
trial	and	there	are	multiple	blocks	of	the	relevant	lesion	available,	what	is	the	most	common	
response	by	your	department?	
Usually	comply	by	submitting	the	paraffin	block	
Usually	comply	by	submitting	the	paraffin	block,	but	with	conditions	(e.g.	must	be	
available	for	return	if	required	and	tissue	must	not	be	exhausted)	
Usually	comply	by	submitting	unstained	sections	
Use	pathologist	discretion	as	to	whether	to	send	the	block	
Decline	all	such	requests	
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Other	(please	specify)	
11. When	receiving	a	request	(with	appropriate	consent)	to	send	tissue	as	part	of	a	clinical
trial	and	only	one	block	is	available,	what	is	the	most	common	response	by	your	
department?	
Usually	comply	by	submitting	the	paraffin	block	
Usually	comply	by	submitting	the	paraffin	block,	but	with	conditions	(e.g.	must	be	
available	for	return	if	required	and	tissue	must	not	be	exhausted)	
Usually	comply	by	submitting	unstained	sections	
Use	pathologist	discretion	as	to	whether	to	send	the	block	
Decline	all	such	requests	
Other	(please	specify)	
12. When	receiving	a	request	to	send	diagnostic	slides	for	central	review	(or	other	purpose)
for	a	clinical	trial,	what	is	the	most	common	response	by	your	department?	
Usually	comply	by	submitting	the	diagnostic	slides	(no	recuts	made)	
Usually	comply	by	submitting	recut	sections	and	keeping	the	original	diagnostic	
sections	in	your	department	
Usually	comply	by	submitting	the	original	diagnostic	slides	and	keeping	recuts	in	the	
department	
Usually	comply	by	submitting	scanned	images	of	the	original	diagnostic	slides	
Decline	all	such	requests	
Other	(please	specify)	
13. If	there	was	a	mechanism	to	quickly	and	easily	retrieve	blocks	upon	request	or	you	could
be	sure	that	the	tissue	would	not	be	exhausted,	would	that	change	your	institution’s	
willingness	to	send	blocks?	
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Yes	
No	
Don't	know	
14. Is	release	dependent	on	the	reporting	pathologist	giving	permission?
Yes	
No	
Don't	know	
15. Do	you	believe	that	there	is	a	duty	on	pathologists	and	pathology	departments	to
maintain	diagnostic	material	in	a	pathology	department	for	future	diagnostic	tests	that	may	
be	required	or	are	developed	in	the	future?	
Yes	
No	
It	depends	on	the	specifics	of	the	consent	form	
Don't	know	
Other	(please	specify)	
Charges	for	tissue	release	
16. Do	you	charge	for	sending	original	diagnostic	blocks	or	slides	for	a	trial?
Yes	(please	specify	cost)	
No	
Other	(please	specify)	
17. Do	you	charge	for	cutting	sections	for	a	trial?
Yes	(please	specify	cost)	
No	
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Other	(please	specify)	
18. Do	you	charge	for	scanning	sections	for	a	trial?
Yes	(please	specify	cost)	
No	
No	(have	no	access	to	scanner)	
Other	(please	specify)	
19. If	you	charge	for	sending	materials	for	research,	have	the	costs	been	factored	in	to	the
research	study?	
Always	
Mostly	
Sometimes	
Never	
Other	(please	specify)	
20. What	percentage	of	tissue	access	requests	originate	from	industry	rather	than
academia?	
Over	50%	
5-50%
Less	than	5%	
Unsure	
21. Do	your	tissue	access	costs	differ	for	industry	requests	versus	academic	requests?
Yes,	industry	is	charged	more	than	academic	requestors	
Yes,	industry	is	charged	less	than	academic	requestors	
No,	they	are	charged	the	same	
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22. Would	you	still	charge	if	the	trial	was	on	the	National	Institute	for	Health	Research
(NIHR)	trial	portfolio?	
Yes	
No	
Other	(please	specify)	
23. How	are	the	staff	and	infrastructure	that	fulfil	research	requests	funded?
University	
Biomedical	Research	Centre	(BRC)	
National	Health	Service	(NHS)	
Mixed	
Other	(please	specify)	
Consent	issues	
24. Does	your	institution	have	a	system	of	collecting	consent	wishes	in	relation	to	surplus
diagnostic	material	when	patients	are	undergoing	surgery	on	the	NHS	consent	to	procedure	
form?	
Yes	
No	
Not	sure	
25. If	you	answered	yes	to	the	above	question,	which	best	describes	the	system?
Robust	
Variable	
Unreliable	
Other	(please	specify)	
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26. Does	your	institution	have	a	specific	biobank	consent	form	that	can	be	used	for	surplus
diagnostic	material?	
Yes	
No	
Not	sure	
27. For	clinical	trials,	do	you	ask	to	see	the	consent	form	before	releasing	tissue?
Yes	–	always	
Yes	–	if	possible	
No	
Don't	know	
Other	(please	specify)	
28. For	research	studies	that	are	not	related	to	a	clinical	trial,	would	you	require	evidence	of
consent	before	releasing	diagnostic	archive	material?	Please	select	one	which	best	applies	to	
your	department.	
Yes	–	always	
Yes	–	if	possible	
No	
Not	necessarily	if	release	is	for	a	Research	Ethics	Committee	(REC)	approved	project,	
the	material	is	from	the	living	and	released	anonymously	(and	you	are	sure	the	
patient	didn’t	decline)	
Don't	know	
Other	(please	specify)	
Other	information	(free	text	responses)	
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29. Do	you	experience	any	other	problems	related	to	submission	of	materials	for	clinical
trials	or	other	research	studies?	
30. Are	there	any	additional	comments	that	you	would	like	to	make	relating	to	this	topic	in
general?	
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Appendix	2	–	Improving	the	quality	of	Web	surveys:	the	Checklist	for	Reporting	Results	of	
Internet	E-Surveys	(CHERRIES)	
1. Design
• Given	the	importance	of	tissue	release	for	clinical	trial	research,	and	to	understand	why
this	is	not	always	achieved,	the	National	Cancer	Research	Institute’s	(NCRI)	Cellular
Molecular	Pathology	(CM-Path)	initiative	decided	to	survey	the	UK’s	cellular	pathology
laboratories	to	ascertain	current	attitudes	and	practices	in	this	area.
2. Institutional	Review	Board	approval	and	informed	consent	process
• As	this	survey	was	not	circulated	to	patients,	the	study	did	not	require	Institutional
Review	Board	approval.
• Participants	were	informed	that	completion	of	the	survey	was	voluntary	and	would	take
about	10	minutes,	that	the	data	would	be	stored	and	analysed	by	individuals	working	for
the	NCRI	and	that	they	would	be	used	to	contribute	to	the	development	of	guidelines	to
standardise	tissue	release	for	clinical	trials	research.
• At	the	end	of	the	survey	period,	all	data	were	downloaded	from	the	website	hosting	the
survey	and	stored	securely.
3. Development	and	pre-testing
• Our	survey	was	developed	by	CM-Path	Clinical	Trials	workstream	members,	based	on
their	own	experiences	and	a	similar	study	conducted	in	the	United	States	of	America
(USA)	[12].
• It	aimed	to	assess:	(1)	current	attitudes	and	practices;	(2)	financial	implications;	and	(3)
barriers	to	tissue	release.
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• The	usability	and	technical	functionality	of	the	electronic	questionnaire	were	tested	by
workstream	members	before	survey	dissemination.
4. Recruitment	process	and	description	of	the	sample	having	access	to	the	questionnaire
• This	was	a	closed	survey,	with	invitations	to	participate	distributed	through	the	NCRI’s
CM-Path	and	Confederation	of	Cancer	Biobanks	(CCB)	mailing	lists.
• As	the	aim	was	to	assess	nationwide	practice,	responses	were	sought	on	a
departmental/institutional	basis;	to	achieve	this,	the	questionnaire	asked	for	the	most
appropriate	individual	in	each	department	to	complete	it.
• We	did	not	specify	who	this	should	be	but	suggestions	of	a	tissue	access	committee
chair	or	head	of	department	were	provided.
5. Survey	administration
• The	questionnaire	was	administered	with	the	use	of	an	online	survey	tool
(www.surveymonkey.com).
• The	survey	was	voluntary	and	no	incentives	were	offered	to	complete	it.
• The	questionnaire	was	distributed	in	November	2016,	with	results	analysed	in	August
2017.
• The	survey	contained	30	questions	spread	over	5	pages.
• Randomisation	of	items	and	adaptive	questioning	were	not	used.
• Whilst	non-response	options	(e.g.	‘not	applicable’/‘rather	not	say’)	were	not	provided,
none	of	the	questions	were	mandatory	and	all	contained	a	‘don’t	know’	or	‘other’
response	option	which	permitted	the	entry	of	a	free	text	answer.
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• Respondents	were	able	to	review	and	change	their	answers	through	the	use	of	a	‘Back’
button.
6. Response	rates
• 220	departments/institutions	included	in	the	NCRI’s	CM-Path	and	CCB	mailing	lists
received	an	invitation	to	participate	in	the	survey.
• We	received	44	responses;	with	the	majority	of	the	UK’s	teaching	hospitals	replying	we
believe	that	our	data	accurately	represent	the	practices	of	departments	involved	in	large
scale	clinical	research.
• Responses	were	received	from	throughout	the	UK	(including	England,	Wales,	Scotland
and	Northern	Ireland).
7. Preventing	multiple	entries	from	the	same	individual
• Duplicate	responses	from	a	single	department/institution	were	identified	through	a
combination	of	the	answers	provided	(e.g.	department/institution	name)	and	Internet
Protocol	(IP)	address.
• Only	the	response	from	the	individual	deemed	most	appropriate	by	the	authors	was
used	in	calculating	summary	statistics.
• 44	individuals	completed	the	survey,	representing	38	different	departments/institutions.
• 6	duplicate	responses	were	excluded	from	quantitative	analyses	(n=38)	but	were
included	in	qualitative	analyses	(n=44).
8. Analysis
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• All	non-duplicate	questionnaires	(n=38),	including	two	that	were	terminated	mid-way
through,	were	included	in	the	final	quantitative	analysis.
• Where	possible,	simple	summary	statistics	were	calculated	to	display	the	response	to
each	question.
• For	questions	that	permitted	free	text	responses,	a	summary	of	replies	was	provided.
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